These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 33986125)

  • 61. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine.
    Madan RA; Redman JM; Karzai F; Dahut WL; Cordes L; Fakhrejahani F; Vu T; Sheikh N; Schlom J; Gulley JL
    J Immunother; 2023 May; 46(4):145-151. PubMed ID: 36821354
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.
    Redman JM; Steinberg SM; Gulley JL
    J Immunother Cancer; 2018 Sep; 6(1):91. PubMed ID: 30227893
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.
    Wei XX; Kwak L; Hamid A; He M; Sweeney C; Flanders SC; Harmon M; Choudhury AD
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):314-319. PubMed ID: 35145218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
    Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
    Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    Small EJ; Lance RS; Gardner TA; Karsh LI; Fong L; McCoy C; DeVries T; Sheikh NA; GuhaThakurta D; Chang N; Redfern CH; Shore ND
    Clin Cancer Res; 2015 Sep; 21(17):3862-9. PubMed ID: 25925891
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Nguyen CB; Reimers MA; Perera C; Abida W; Chou J; Feng FY; Antonarakis ES; McKay RR; Pachynski RK; Zhang J; Reichert ZR; Palmbos PL; Caram MEV; Vaishampayan UN; Heath EI; Hopkins AC; Cieslik MP; Wu YM; Robinson DR; Baladandayuthapani V; Chinnaiyan AM; Alva AS
    Clin Cancer Res; 2024 Aug; 30(15):3200-3210. PubMed ID: 38787530
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
    Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
    Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).
    Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM
    Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
    Cha E; Small EJ
    Cancer Med; 2013 Apr; 2(2):243-52. PubMed ID: 23634292
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer.
    Kittai A; Meshikhes M; Aragon-Ching JB
    Cancer Biol Ther; 2014 Oct; 15(10):1299-300. PubMed ID: 25046606
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modeling the effect of immunotherapies on human castration-resistant prostate cancer.
    Coletti R; Pugliese A; Marchetti L
    J Theor Biol; 2021 Jan; 509():110500. PubMed ID: 32980372
    [TBL] [Abstract][Full Text] [Related]  

  • 76. New approaches to immunotherapy for metastatic castration-resistant prostate cancer.
    Subudhi SK
    Clin Adv Hematol Oncol; 2019 May; 17(5):283-286. PubMed ID: 31188806
    [No Abstract]   [Full Text] [Related]  

  • 77. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
    Chae YK; Othus M; Patel S; Powers B; Hsueh CT; Govindarajan R; Bucur S; Kim HS; Chung LI; McLeod C; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke C; Kurzrock R
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39343510
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CTLA-4 Expression and Its Clinical Significance in Breast Cancer.
    Kern R; Panis C
    Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):16. PubMed ID: 34148159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
    Friedman CF; Spencer C; Cabanski CR; Panageas KS; Wells DK; Ribas A; Tawbi H; Tsai K; Postow M; Shoushtari A; Chapman P; Karakunnel J; Bucktrout S; Gherardini P; Hollmann TJ; Chen RO; Callahan M; LaVallee T; Ibrahim R; Wolchok J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074903
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Current status and prospects of immunotherapy for castration-resistant prostate cancer].
    Yatsuda J; Eto M
    Nihon Rinsho; 2014 Dec; 72(12):2174-8. PubMed ID: 25518354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.